The goal of this study is to evaluate the safety and tolerability of TG-C in subjects with chronic discogenic lumbar back pain due to degenerative disc disease. Participants will be administered a single intradiscal injection or subcutaneous injection for sham and followed up with in-clinic visits and telephone calls for 24 months.
Between the ages of >= 22 and <= 70
Provides written informed consent before undergoing any study specific procedures
Chronic lower back pain for at least 6 months. Back pain twice as great as leg pain measured using NRS
VAS between >= 40 and <= 90
Co-morbid medical condition of the spine or upper extremities
Grade 2 or higher spondylolisthesis and type III Modic changes around target disc
Suspicion of full thickness annular tear at disc
History of endocrine or metabolic disorder